Loading...
Loading...
Cytokinetics, Incorporated
CYTK announced today that CK-2017357, its fast skeletal muscle troponin activator, has received Fast Track designation from the U.S. Food and Drug Administration for the potential treatment of amyotrophic lateral sclerosis, also commonly known as Lou Gehrig's Disease. CK-2017357, the lead drug candidate from the company's skeletal sarcomere activator program, is currently in Phase II clinical trials intended to inform a potential registration program.
Cytokinetics anticipates that results from two recently completed Phase II clinical trials, designed to assess the safety and tolerability of CK-2017357 in patients with ALS, will be presented at the American Academy of Neurology 64th Annual Meeting in New Orleans, LA on April 25, 2012.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in